About Abyrx
Abyrx is a company based in Irvington (United States) founded in 2013. Abyrx has raised $10 million across 1 funding round from investors including Canaan, BB Biotech Ventures and MedEdge Solutions. Abyrx has completed 1 acquisition, including ORTHOCON. Abyrx offers products and services including MONTAGE, Hemostatic Bone Putty, and Hemostatic Bone Putty in Syringe. Abyrx operates in a competitive market with competitors including Biom'Up, Prytime Medical Devices, Endomedix, United Health Products and LifeBond, among others.
Products & Services of Abyrx
Abyrx offers a comprehensive portfolio of products and services, including MONTAGE, Hemostatic Bone Putty, and Hemostatic Bone Putty in Syringe.
Settable, resorbable hemostatic bone putty for surgical bleeding control.
Water-soluble putty for stopping bone bleeding in medical procedures.
Syringe applicator for precise hemostatic bone putty delivery.
Funding Insights of Abyrx
Abyrx has successfully raised a total of $10M through 1 strategic funding round. The most recent funding activity was a Series A round of $10 million completed in December 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $10M
- Total Rounds 1
- Last Round Series A — $10M
- First Round $10M
(Dec 2016)
- Investors Count 3
All 1 funding rounds of Abyrx with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2016 | $10M | Series A | – | – |
3 investors in total: 3 institutional.
Investors in Abyrx
Abyrx has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include Canaan, BB Biotech Ventures and MedEdge Solutions.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Canaan is recognized as an early-stage venture capital firm. | 1987 | canaan.com | San Francisco, United States | |
- | – | bbbiotechventures.com | - | |
MedEdge Solutions is focused on pharmacy data and management solutions. | – | mededgesolutions.com | - |
Investor details for Abyrx
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Abyrx
18 people are tracked at Abyrx (5 in leadership, 6 in board & advisors, 7 in team).
| Name | Role | Group |
|---|---|---|
John J. Pacifico | President & CEO, Board Member | Leadership |
Richard L. Kronenthal | Chief Scientific Officer | Leadership |
Aniq Darr | VP, Product Development & Quality Affairs | Leadership |
Joe Purritano | Vice President, Commercial Operations | Leadership |
Alyssa McDermott | Sr. Director Of Regulatory And Quality Affairs | Leadership |
Alan Levy | Board Member | Board & advisors |
Seth Rudnick | Advisor | Board & advisors |
Brent Ahrens | Board Member | Board & advisors |
Gary D. Cohn | Board Member | Board & advisors |
John Sfondrini | Board Member | Board & advisors |
Dennis Podlesak | Advisor | Board & advisors |
Elizabeth Gianino | Product Development Engineer | Team |
Jenny Holloway | Business Operations Manager | Team |
Matt Squazzo | Operations Manager | Team |
Jan Lessem | AVP, Clinical & Medical Affairs | Team |
Rao S. Bezwada | AVP, Polymer & Chemistry Development | Team |
Bryant Heimbach | Senior Product Development Engineer | Team |
Ken Kowalski | Agent For Abyrx "montage" | Team |
Complete people profiles for Abyrx
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Abyrx
Abyrx has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include ORTHOCON.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Resorbable hemostatic bone putty is developed to stop surgical bleeding. | orthocon.com | Irvington, United States | 2005 | Apr 2013 | •••• |
Complete acquisition details for Abyrx
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Abyrx
3 dated milestones of Abyrx across 3 years, from founding to its latest funding, stage changes and deals.
- Founded Abyrx is founded.
- Acquisition Acquires ORTHOCON.
- Funding First funding round of $10.0M.
Competitors of Abyrx
Abyrx operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biom'Up, Prytime Medical Devices, Endomedix, United Health Products and LifeBond, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| biomup.com | 2005 | Saint Priest Bramefant, France | $43.82M | – | Hemostatic products for surgical applications are developed using collagen-based materials. | |
| prytimemedical.com | 2011 | Boerne, United States | $10M | 41 | Developer of minimally invasive large vessel occludes for hemorrhage control in trauma patients | |
| endomedix.com | 2005 | Newark, United States | $1.99M | – | Hydrogel solutions for surgery and wound care are developed. | |
| uhpcorp.com | 1997 | Mesquite, United States | – | – | Medical device for hemostasis during surgical procedures is provided. | |
| life-bond.com | 2007 | Caesarea, Israel | $56.5M | – | Absorbable surgical sealants and hemostats are developed for leakage prevention. | |
| obsidiomed.com | 2018 | Solana Beach, United States | $3M | – | Shear-thinning biomaterial is developed to control blood flow minimally invasively. | |
| fusionmed.com | 1992 | Fremont, United States | – | – | Collagen-derived particles and thrombin are utilized for surgical hemostasis. | |
| archtherapeutics.com | 2006 | Natick, United States | $320,000 | 8 | Hemostasis and sealant technology | |
| surgrx.com | 2001 | Redwood, United States | $62.5M | – | Tissue sealing and hemostasis systems are developed for laparoscopic surgery. |
Detailed competitors of Abyrx
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Abyrx
The website of Abyrx (abyrx.com) receives about 1.5K visits a month.
- Monthly visits1.5K
▼ 1.2% vs previous month
Latest news on Abyrx
Complete news archive for Abyrx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Abyrx
10 companies that operate in the same segment as Abyrx (Orthopedics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Provider of high-frequency spinal cord stimulation implants | 2006 | Menlo Park, California, United States | USD 154.1 M | USD 353.08 M | 1,215 | |
Prosthetic and orthotic devices are developed for individuals with disabilities. | 1919 | Duderstadt, Lower Saxony, Germany | USD 17 M | USD 1.97 B | – | |
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
Developer of drugs for treating rare and autoimmune diseases | 2008 | Dublin, Ireland | USD 61.78 M | USD 617.41 M | – | |
Antibody-siRNA complexes are developed for cancer treatment. | 2012 | San Diego, California, United States | USD 142.54 M | USD 10.9 M | 391 | |
Smart surgical devices for spinal surgery are developed. | 1997 | San Diego, California, United States | USD 54.1 M | – | – | |
Robotic arms are provided for mobility and rehabilitation support. | 2004 | Boston, Massachusetts, United States | USD 17.21 M | USD 40.93 M | 185 | |
AI-powered drug discovery platform for various diseases | 2016 | New York, New York, United States | USD 608 M | – | – | |
Exoskeletons for medical rehabilitation and industrial productivity are provided. | 2005 | United States | USD 24.37 M | USD 71.6 M | 61 | |
Stabilization devices for healthcare are manufactured by the company. | 2005 | New York, New York, United States | USD 142.15 M | – | 43 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Abyrx
Abyrx was founded in 2013 and raised its 1st funding round 3 years after it was founded.
Abyrx is headquartered in Irvington, United States. It is registered at Irvington, New Jersey, United States.
Abyrx is a funded company, having raised a total of $10M across 1 funding round to date. The company's 1st funding round was a Series A of $10M, raised on Dec 2016.
Abyrx was founded in 2013 and is headquartered in Irvington, United States. Hemostatic bone putty is developed by the company for use in surgical procedures to control bone bleeding. A portfolio of three FDA-cleared putties, which are resorbable and synthetic without tissue components, is maintained. Over 40 issued and pending patents are held. The HEMASORB Resorbable Hemostatic Bone Putty portfolio was acquired to expand offerings in the medical device sector.
Abyrx's top competitors include Prytime Medical Devices, Arch Therapeutics and Biom'Up.
Abyrx offers MONTAGE, Hemostatic Bone Putty, and Hemostatic Bone Putty in Syringe.
Abyrx has made 1 acquisition, including ORTHOCON.
Abyrx has 3 investors. Key investors include Canaan, BB Biotech Ventures, and MedEdge Solutions.
Abyrx operates through Abyrx, Inc..